DOI: 10.1158/1078-0432.ccr-26-2134 ISSN: 1078-0432
BRIGHTLINE-1: When a Negative Trial Reveals Two Active Therapies
Adel Shahnam, Mrinal M. GounderAbstract
Although BRIGHTLINE-1 was headlined as a “negative trial,” brigimadlin showed clear biological activity, with median PFS of 8.4 months, ORR of 22.3%, and translational evidence of p53 reactivation. Its failure largely reflects flawed control-arm assumptions, as doxorubicin outperformed retrospective expectations and established a new prospective benchmark in DDLPS.